| Journal: | Annals of hepatology |
| Database: | PERIÓDICA |
| System number: | 000416308 |
| ISSN: | 1665-2681 |
| Authors: | Camargo Pinheiro Alves, Rogério1 Alves, Daniele2 Guz, Betty1 Matos, Carla3 Viana, Monica1 Harriz, Michele1 Terrabuio, Deborah1 Kondo, Mario3 Gampel, Otavio2 Polletti, Paula1 |
| Institutions: | 1Hospital do Servidor Publico Estadual de Sao Paulo "Francisco Morato de Oliveira", Departamento de Gastroenterologia, Sao Paulo. Brasil 2Hospital do Servidor Publico Estadual de Sao Paulo "Francisco Morato de Oliveira", Departamento de Oncologia, Sao Paulo. Brasil 3Hospital A.C. Camargo, Departamento de Hepatologia, Sao Paulo. Brasil |
| Year: | 2011 |
| Season: | Ene-Mar |
| Volumen: | 10 |
| Number: | 1 |
| Pages: | 21-27 |
| Country: | México |
| Language: | Inglés |
| Document type: | Artículo |
| Approach: | Analítico, descriptivo |
| English abstract | Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world in terms of incidence, accounting for approximately 630 thousand new cases per year; in addition, HCC is the third most common cause of cancer death. Worldwide, the greatest risk factors for HCC are the infections caused by hepatitis B and C viruses, which increase the risk of developing the disease by about 20 times. The standard treatment in the early stages of the disease, such as surgical resection, local ablation and liver transplantation, are able to cure a proportion of patients, but most cases of HCC present in advanced stages, precluding the use of such treatments with curative intent. In these advanced stages, systemic treatments are commonly used. Unfortunately, chemotherapy with conventional cytotoxic agents is ineffective and does not seem to modify the natural history of disease. Treatment options for patients with advanced HCC are extremely limited, but the identification of signaling pathways, and the recognition of the role of these pathways in the pathogenesis of the disease resulted in the development of drugs directed at specific therapeutic targets. One such drug is Sorafenib, a kinase inhibitor with antiangiogenic and antiproliferative properties. In conclusion, Sorafenib has demonstrated survival benefits in patients with advanced HCC, thus representing a new standard reference for systemic treatment in these cases |
| Disciplines: | Medicina |
| Keyword: | Gastroenterología, Oncología, Farmacología, Carcinoma hepatocelular, Patogénesis, Medicina molecular, Blancos terapéuticos, Sorafenib |
| Keyword: | Gastroenterology, Oncology, Pharmacology, Hepatocellular carcinoma, Pathogenesis, Molecular medicine, Therapeutic targets, Sorafenib |
| Full text: | Texto completo (Ver PDF) |
